Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicon HoldingsADCNF 73 Equity-to-Asset is 0.36 as of Dec. 2025, which is at its 10-year median of 0.36. GuruFocus rates ADCNF with a GF Score™ of 73/100 and a GF Value™ of $1.35. The stock has 6 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Adicon Holdings ranks worse than 76.67% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Adicon Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $244.3 Mil. Adicon Holdings's Total Assets for the quarter that ended in Dec. 2025 was $682.0 Mil.
Therefore, Adicon Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.36.
The historical rank and industry rank for Adicon Holdings's Equity-to-Asset or its related term are showing as below:
ADCNF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.36 Max: 0.38
Current: 0.36
During the past 6 years, the highest Equity to Asset Ratio of Adicon Holdings was 0.38. The lowest was 0.11. And the median was 0.36.
ADCNF's Equity-to-Asset is ranked worse than 76.67% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs ADCNF: 0.36
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Adicon Holdings Equity-to-Asset Related Terms
Adicon Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Adicon Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCNF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Adicon Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicon Holdings Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adicon Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Adicon Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Adicon Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicon Holdings (ADCNF) has a Equity-to-Asset of 0.36 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Adicon Holdings and its competitors. This is near median its historical median of 0.36. Over the past decade, Adicon Holdings' Equity-to-Asset has ranged from 0.11 to 0.38. According to the industry distribution chart, Adicon Holdings ranks #161 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 76.7%.
Is Adicon Holdings' Equity-to-Asset too high?
Adicon Holdings' current Equity-to-Asset of 0.36 is near median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.38. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Adicon Holdings' value of 0.36 is 39% below this industry median. Based on the distribution chart, Adicon Holdings ranks #161 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adicon Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Adicon Holdings' Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Adicon Holdings ranks #161 out of 210 companies for Equity-to-Asset. This places Adicon Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Adicon Holdings' value of 0.36 is 39% below this benchmark. Historically, Adicon Holdings' own Equity-to-Asset has ranged from 0.11 to 0.38 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.59, Adicon Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicon Holdings's current Equity-to-Asset of 0.36 is 39% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Adicon Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicon Holdings's current Equity-to-Asset is 0.36, which is near median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicon Holdings stock overvalued right now?
Adicon Holdings (ADCNF) has a current Equity-to-Asset of 0.36. The stock's GF Value™ is $1.35, compared to a current price of $0.65 — trading 51.9% below its estimated fair value. The current Equity-to-Asset is 0.36, which is near median its 10-year median of 0.36 and 39% below the Medical Diagnostics & Research industry median of 0.59. Adicon Holdings' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Adicon Holdings (ADCNF), the current Equity-to-Asset is 0.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicon Holdings (ADCNF) Overvalued in 2026?
Based on GuruFocus' analysis, Adicon Holdings stock appears to be undervalued.
The current stock price of $0.65 is trading 51.9% below its estimated GF Value™ of $1.35.
Key valuation signals for ADCNF:
Equity-to-Asset: 0.36 (near median its 10-year median of 0.36)
GF Value™: $1.35 vs. price of $0.65 (51.9% below fair value)
Industry Position: 39% below the Medical Diagnostics & Research median (#161 of 210)
No single metric tells the full story. See the ADCNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicon Holdings Ltd is a ICL service provider in China. It offers comprehensive testing services to hospitals and health check centers through an integrated network of self-operated laboratories across China. Its testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, consisting of over 4,000 medical diagnostic tests, the introduction of over 300 new high-end diagnostic tests.
73GF Score
Get the complete analysis for ADCNF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCNF has been successfully added to your 
